The Offer

Company Overview

An international pioneering biotechnology company, Virax Cayman specializes in the marketing, sales, and distribution of medical technologies, personal protective equipment, and diagnostic test kits for the treatment of viral infections. The company has a specific focus on immunology.

Key Highlights

Primary Offering: The company is issuing 1,350,000 shares at USD 5.00. The corporate assessments for the net proceeds from this offering, assuming an initial public offering at USD 5.00 per share and full execution of the underwriters' option to acquire further shares, will be around USD 7,037,725. Additional 7% underwriter warrants are also granted; these warrants have a cashless exercise clause and are exercisable for three years after the date of issuance.

Use of proceeds:

Dividend policy: The firm did not declare any dividends for the fiscal years ending March 31, 2021, and 2020. The firm also aims to keep all available money and any future revenues to fund the growth and expansion of its business and does not anticipate declaring or paying dividends in the near future.

Sector Analysis

• In the market for in-vitro diagnostics (IVD), VRAX is a competitor. In most cases, IVD tests are carried out at point-of-care (POC) facilities, clinic laboratories, or independent research labs. The IVD market was estimated by Netscribes to be worth about USD 75.0 billion (FY2021E). In the following five years, it might increase at a CAGR of about 5.2 percent (2020–2025), which would be modest growth rates.

• The IVD sector is constantly growing and is anticipated to go through profitable expansion rates due to driving considerations like the aging worldwide residents, an increase in intensity in the incidence of multifaceted infectious ailments, an upsurge in mindfulness among the universal built-up inhabitants, etc.  However, there are still barriers in some areas, particularly in third-world nations, which restrain the expansion of the IVD business, improper compensation systems, and patient resistance to receiving frequent healthcare consultations.
• Five major companies control more than half of the IVD market, as seen in the pie chart below. Roche is now dominating the worldwide IVD market in part because of its wide product range and high level of automation, even if the IVD industry is consolidating as a result of major ongoing M&A efforts.

Financial Highlights (Expressed in USD):

• Increasing revenues: The company reported revenue of USD 123,820 for FY21, which was 23.97% higher than the revenue of USD 99,876 reported in FY20.
• Decline in Operating losses: During FY21, the company’s operating losses were USD 644,538 compared to USD 651,244 in FY20, mainly because of reduction in general and administration expenses and partially offset by increase in Sales and marketing and R&D expenses.
• Narrowing Bottom line losses: The net loss for the company has decreased in FY21 to USD 676,616 from USD 739,464 in FY20. The main reason for this decrease is the reduction in general and administration costs.

Key Management Highlights

Risk Associated (High

Investment in the IPO of “VRAX” is exposed to a variety of risks such as:

• Operational and profitability risk: Due to the company's short history of operations, operational losses were reported for the three years ended March 31, 2020, the six months ended September 30, 2021, respectively. Going forward It is possible that VRAX faces challenges to turn profitable or won't be able to maintain adequate profitability margins.
• Trial failure risks: The business's attempts to create the T-Cell In-Vitro Diagnostic Test could not be effective, and it might not produce the insights the company anticipates in any way or by the timeframe required for VRAX to develop or market any new diagnostic solutions. Additionally, VRAX is now working on a brand-new COVID-19 test called Virax Immune that looks for T-cell immune responses to the SARS-Cov2-virus.
• Volatility in the Broader market: Over the last six months markets are quite volatile because of series of macro event took place ranging from Russia-Ukraine standoff, supply chain disruption, multiyear high inflation across the globe, rising energy prices, COVID led lockdown in China and others. These macro events could continue to have a weigh on the broader market sentiment.

Conclusion

VRAX reported decent financial performance in FY21 with surge in the topline and narrowing losses on a YoY basis. However, given the variety of uncertainties hovering over the global financial markets, a listing gain on a loss-making company could be challenging. However, the industry in which VRAX operates is growing decently and expected to grow moderately in the coming years.

Hence, Virax Biolabs Group Limited (VRAX) IPO looks "Neutral” at the current price and in the present market scenario, given the risks associated.

---

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.